Search

Jianhua Sui

from Waltham, MA
Age ~53
Get Report
Also known as:
Jian Hua Sui
Related to:
Jian-Hua Sui
Connected to:
Ai L Sui, 37Daniel Y Sui, 32Jennifer Sui, 34Joe Sui, 89Juan Sui, 43Lin Sui, 46Margaret N Sui, 51Ng K Sui, 70Ning Sui, 35Sara Sui, 32

Jianhua Sui Phones & Addresses

  • Waltham, MA
  • 1575 Tremont St, Roxbury, MA 02120
  • West Roxbury, MA
  • Seattle, WA
  • Stoneham, MA

Work

Company: Dana-farber cancer institute Position: Instructor

Industries

Research

Resumes

Resumes

Jianhua Sui Photo 1

Instructor

View page
Location:
Boston, MA
Industry:
Research
Work:
Dana-Farber Cancer Institute
Instructor

Publications

Us Patents

Antibodies Against Cxcr4 And Methods Of Use Thereof

View page
US Patent:
8329178, Dec 11, 2012
Filed:
Feb 15, 2006
Appl. No.:
11/883258
Inventors:
Wayne A. Marasco - Wellesley MA, US
Jianhua Sui - Boston MA, US
Chen Xu - Beijing, CN
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
A61K 39/395
C07K 16/28
C07K 14/47
C07K 16/46
C07K 14/715
US Classification:
4241431, 4241331, 4241351, 530350, 5303873, 53038822, 530324, 530402
Abstract:
The invention provides human monoclonal antibodies or fragments thereof, that specifically bind to CXCR4. Disclosed are methods of use of such antibodies for the treatment and/or prevention of a CXCR4 disease or disorder such as cancer and X4-tropic HIV-1 infection Also provided are methods of use of such antibodies and antibody fragments for the treatment or prevention of cancer metastasis. The invention provides methods of mobilizing CD34stem cells from the bone marrow and methods of blocking chemotaxis of CXCR4-expressing cells in response to SDF-1. Also provided are methods of use of the antibodies and fragments thereof for the prevention or treatment of graft-versus-host disease. Finally, the invention provides methods of inhibiting new tumor blood vessel formation and/or tumor cell angiogenesis.

Antibodies Against Sars-Cov And Methods Of Use Thereof

View page
US Patent:
20050249739, Nov 10, 2005
Filed:
Nov 24, 2004
Appl. No.:
10/997201
Inventors:
Wayne Marasco - Wellesley MA, US
Jianhua Sui - Boston MA, US
International Classification:
A61K039/42
C07K016/10
US Classification:
424159100, 530388300
Abstract:
The invention provides scFv antibodies and monoclonal antibodies that neutralize SARS-CoV. Also provided are methods of treating and/or preventing a coronavirus-related disease or disorder such as SARS. The invention also provides methods of vaccinating a patient against SARS-CoV. Also provided are methods of diagnosing coronavirus-related diseases or disorders and methods of detecting the presence of a coronavirus in a sample. The invention additionally provides methods of screening for compounds that modulate the binding of SARS-CoV and the SARS-CoV receptor ACE2 as well as for compounds useful to treat SARS-CoV-related diseases or disorders.

Antibodies To West Nile Virus Polypeptides

View page
US Patent:
20090130123, May 21, 2009
Filed:
Jun 15, 2005
Appl. No.:
11/629825
Inventors:
Erol Fikrig - Guilford CT, US
Hannah Gould - New Haven CT, US
Raymond A. Koski - Old Lyme CT, US
Michel Ledizet - Woodbridge CT, US
Wayne A. Marasco - Wellesley MA, US
Jianhua Sui - Boston MA, US
International Classification:
A61K 39/395
C07K 16/18
C12N 5/06
C12N 15/11
C12N 15/00
C12P 21/04
A01K 67/027
A01H 5/00
A61K 31/7088
C12Q 1/70
US Classification:
4241591, 5303871, 5303873, 435339, 536 2353, 4353201, 435 696, 800298, 800 13, 514 44, 800 3, 435 5
Abstract:
The present invention relates to anti-West Nile virus E protein (WNE) antibodies, including human antibodies, and antigen-binding portions thereof. In particular, the invention relates to such antibodies and portions that prevent, inhibit, or treat a flavivirus infection, including a West Nile Virus infection. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or that are portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-WNE antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-WNE antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis, prophylaxis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-WNE antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Antibodies Against Influenza Virus And Methods Of Use Thereof

View page
US Patent:
20110038935, Feb 17, 2011
Filed:
Dec 8, 2008
Appl. No.:
12/746622
Inventors:
Wayne A. Marasco - Wellesley MA, US
Jianhua Sui - Boston MA, US
Robert C. Liddington - La Jolla CA, US
International Classification:
A61K 39/42
C07K 16/10
C07H 21/00
A61K 39/145
A61K 9/00
C12Q 1/70
A61P 31/16
A61P 37/04
US Classification:
424484, 5303873, 53038815, 536 2353, 4241351, 4241421, 4242101, 435 5, 5303883
Abstract:
The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.

Conserved Hemagglutinin Epitope, Antibodies To The Epitope And Methods Of Use

View page
US Patent:
20120128684, May 24, 2012
Filed:
Aug 25, 2009
Appl. No.:
13/061026
Inventors:
Wayne Marasco - Wellesley MA, US
Jianhua Sui - Boston MA, US
Robert C. Liddington - La Jolla CA, US
Assignee:
Burnham Institute for Medical Research - La Jolla CA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
A61K 39/395
C12N 15/44
A61K 39/145
C07K 19/00
A61P 31/16
C12Q 1/70
C07K 1/00
C07K 16/10
A61P 37/04
C07K 2/00
C12N 15/62
US Classification:
4241471, 530300, 536 2372, 4242101, 4241591, 530350, 536 234, 4241921, 530402, 435 5, 5303894
Abstract:
Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both.

Humanized Monoclonal Antibodies And Methods Of Use

View page
US Patent:
20130243749, Sep 19, 2013
Filed:
Jun 2, 2011
Appl. No.:
13/700974
Inventors:
Wayne A. Marasco - Wellesley MA, US
Jianhua Sui - Stoneham MA, US
Yuval Avnir - Boston MA, US
Assignee:
Dana Farber Cancer Institute, Inc. - Boston MA
International Classification:
C07K 16/42
A61K 39/395
A61K 39/145
US Classification:
4241311, 5303872, 5303917, 435327, 4241781
Abstract:
Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.

Human Monoclonal Anti-Pd-L1 Antibodies And Methods Of Use

View page
US Patent:
20200385482, Dec 10, 2020
Filed:
Mar 30, 2020
Appl. No.:
16/834901
Inventors:
- Boston MA, US
Jianhua Sui - Waltham MA, US
International Classification:
C07K 16/28
C07K 16/30
C07K 16/40
C07K 16/24
C07K 16/46
Abstract:
The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.

Human Monoclonal Anti-Pd-L1 Antibodies And Methods Of Use

View page
US Patent:
20180346587, Dec 6, 2018
Filed:
Nov 22, 2017
Appl. No.:
15/821087
Inventors:
- Boston MA, US
Jianhua SUI - Waltham MA, US
International Classification:
C07K 16/28
C07K 16/30
C07K 16/40
C07K 16/46
C07K 16/24
Abstract:
The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.
Control profile
Jianhua Sui from Waltham, MA, age ~53 Get Report